Αποτελέσματα Αναζήτησης
In one study, cutaneous reactions within 3 days after receiving the vaccine were reported in 1.9% of individuals after receiving their first dose of the mRNA COVID vaccine (Pfizer-BioNtech and Moderna). The majority of cutaneous reactions after COVID-19 vaccination occur in women (around 90%).
McMahon et al. have conducted a study regarding post-vaccination rash in 414 patients who reported symptoms of rash. This study compared the rashes developed among those who took the Pfizer-BioNTech (BNT162b2) vaccines with those who received the Moderna (mRNA-1273) COVID-19 vaccine.
15 Απρ 2021 · Large rashes near the vaccine injection site were the most commonly reported reactions in the study. These are often nicknamed "COVID arm" or "Moderna arm," as they seem to follow Moderna's...
A male patient in his early 20s presented to the allergy clinic eight weeks after receiving his second dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in March 2021 for a recurrent rash. The patient had no chronic medical conditions and had not been diagnosed with COVID-19 in the past.
Type IV hypersensitivity reactions may be observed, including delayed large local skin lesions ("COVID arm"), inflammatory reactions in dermal filler or previous radiation sites or even old BCG scars, and more commonly morbilliform and erythema multiforme-like rashes.
25 Μαρ 2022 · Of the patients that do have a rash, about 20 percent will develop the rash either as their only sign and symptom of COVID-19 or their first sign and symptom of COVID-19,” says Dr. Freeman. “In fact, you’re more likely to develop a skin reaction from COVID-19 itself than you are to develop a serious skin reaction from the COVID vaccine."
Studies describing clinical cutaneous adverse reactions after at least one dose of mRNA (Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273) or adenovirus-vectored (AstraZeneca/Oxford AZD1222 and Johnson & Johnson/Janssen Ad26.CoV2.S) SARS-CoV-2 vaccine were included.
